KCNJ10 and myeloid sarcoma: In 2012, Srivastava and colleagues [22] identified IgG1 and IgG3 antibodies that bind glial cells in human brain tissue in the serum of MS patients and demonstrated that the molecular target of these antibodies was the potassium channel KIR4.1.